Exemestane seems to stimulate tumour growth in men with prostate carcinoma [2]

European Journal of Cancer

Volumn 39, Issue 14, 2003, Pages 2111-2112

  Bonomo, Marco ^a   Mingrone, Walter ^a   Brauchli, Peter ^a   Hering, Franz ^a   Goldhirsch, Aron ^a  

^a Swiss Inst for Appl Cancer Res   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; EXEMESTANE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANALGESIA; ANEMIA; BONE PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FRACTURE; GENDER; GROWTH STIMULATION; HUMAN; LETTER; LUNG METASTASIS; MALE; MEDICAL DOCUMENTATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR GROWTH; TUMOR REGRESSION; CELL DIVISION; CHEMICALLY INDUCED DISORDER; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0142058148     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00486-6     Document Type: Letter

References (13)

1. Huggins C., Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatica carcinoma of the prostate Cancer Res. 1:1941;293-297.
2. Huggins C.et al. Studies on prostatic carcinoma. II. The effect of castration on advanced carcinoma of the prostate gland Arch. Surg. 43:1941;209-233.
3. Small E.J., Vogelzang N.J. Second-line hormonal therapy for advanced prostate cancer. a shifting paradigm J. Clin. Oncol. 15:1997;382-388.
4. Caldiroli M.et al. Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer. single institutional experience Eur. Urol. 39(Suppl. 2):2001;6-10.
5. Kelly W.K. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur. Urol. 34(Suppl. 3):1998;18-23.
6. Small E.J.et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157:1997;1204-1207.
7. Castagnetta L.A.et al. Product of aromatase activity in intact LNCaP and MCF-7 human cancer cells. J. Steroid Biochem. Mol. Biol. 61:1997;287-292.
8. Tsugaya M.et al. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int. J. Urol. 3:1996;292-296.
9. Hiramatsu M.et al. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate. 31:1997;118-124.
10. Negri-Cesi P.et al. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. Prostate. 41:1999;224-232.
11. Davies J.H., Dowsett M.et al. Aromatase inhibition. 4- hydroxyandrostenedione in advanced prostatic cancer Br. J. Cancer. 66:1992;139-142.
12. Shearer R.J., Davies J.H., Dowesett M.et al. Aromatase inhibition in advanced prostatic cancer. preliminary communication Br. J. Cancer. 62:1990;275-276.
13. Santen R.J.et al. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer. 92:2001;2095-2101.